Prostate cancer (PCa) is the second most prevalent cancer in people aged ≥50 years and poses a substantial burden on the healthcare system all over the world.[1] With superior cancer control and functional outcomes, radical prostatectomy (RP) has become the gold standard treatment for localized PCa.[2] However, approximately 40% of patients who undergo RP will experience biochemical recurrence (BCR),[3] which is defined as an elevation in prostate-specific antigen (PSA) levels. The gene discussed is KLK3; the disease is cancer.